(Reuters) – Europe’s medicines regulator said on Monday it was evaluating data on a booster dose for the COVID-19 vaccine developed by Pfizer/BioNTech, to be given six months after the second dose in people aged 16 years and older.
The European Medicines Agency said it would carry out a speedy evaluation of the data, with an outcome expected “within the next few weeks”. It also added that it was also assessing data on the use of an additional dose of mRNA vaccines in people with weak immune systems.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Kevin Liffey)
